Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint

Simply Wall St.04-06

In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625962459?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-06 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625962459","market":"hk","top_or_hot":-1,"title":"Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-106-after-brazil-pa\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-06 10:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-106-after-brazil-pa><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-106-after-brazil-pa\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-106-after-brazil-pa","article_id":"2625962459","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-106-after-brazil-pa","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625962459","pubTimestamp":1775441634,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo.\nThis filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","CRNX":"Crinetics Pharmaceuticals Inc.","BK4587":"ChatGPT概念","BK4007":"制药","BK4588":"碎股","AI":"C3.ai, Inc.","BK4528":"SaaS概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4023":"应用软件","BK4585":"ETF&股票定投概念","BK4139":"生物科技","AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AGIX":"通用人工智能 ETF-AGIX","BK4543":"AI","ARTY":"ISHARES FUTURE AI & TECH ETF"},"translate_title":"为什么巴西PALSONIFY申请扩大全球足迹后Crinetics Pharmaceuticals(CRNX)上涨10.6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.82,"ARTY":0.72,"AIYY":0.6,"CRNX":1.5,"AI":0.72,"CHAT":0.72,"AGIX":0.72},"content_text":"In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo. This filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP opinion in Europe, underscoring Crinetics’ efforts to build a global acromegaly franchise while advancing paltusotine into Phase 3 development for carcinoid syndrome. Next, we’ll examine how this Brazil MAA for PALSONIFY, supported by extensive Phase 3 data, may influence Crinetics’ broader investment narrative. This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.AdvertisementCrinetics Pharmaceuticals Investment Narrative RecapTo own Crinetics, you need to believe PALSONIFY can become a meaningful oral standard in acromegaly while the broader endocrine pipeline matures, despite current losses and cash burn. The Brazil MAA builds on US and European progress but does not by itself change the near term focus on U.S. launch execution or the key risk that prescription uptake and payer access may fall short of expectations. The recent resignation of Chief Development and Operating Officer Jeff Knight is the most relevant nearby event, given Crinetics’ dependence on complex, late stage programs like PALSONIFY and paltusotine in carcinoid syndrome. Management says responsibilities are being reassigned internally, but with multiple Phase 3 trials ongoing, any disruption to development or operational continuity could affect timelines and, in turn, the path to future revenue diversification. However, investors should also be aware that if PALSONIFY uptake remains slower than hoped, the combination of heavy spending and the possibility of future dilution could... Read the full narrative on Crinetics Pharmaceuticals (it's free!)Crinetics Pharmaceuticals' narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This would require 566.4% yearly revenue growth and a roughly $518 million earnings increase from -$423.1 million today.Uncover how Crinetics Pharmaceuticals' forecasts yield a $82.43 fair value, a 121% upside to its current price.Exploring Other PerspectivesCRNX 1-Year Stock Price Chart Some of the most optimistic analysts were assuming revenue could reach about US$534.2 million by 2028, yet this Brazil filing and the risk that trial or reimbursement hurdles could slow diversification show how far opinions can differ and why you may want to compare several viewpoints before deciding what you believe.Explore 4 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be a potential multi-bagger!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.Seeking Other Investments?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625962459","isCrawlerRequest":true}